Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

No longer available 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 30Sarcoma 8Other solid neoplasm 5Genitourinary 5Gastrointestinal 3Lymphoid 2Gynecologic 2Endocrine 2Other hematologic neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Pheochromocytoma 2Neuroblastoma 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1Adrenocortical Carcinoma 1

Interventions

3-Iodobenzylguanidine 7gallium Ga 68 dotatate 4fluorodopa F 18 3pegfilgrastim 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 23-fluorobenzylguanidine 2tipifarnib 1pertuzumab 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1entrectinib 1cixutumumab 1arginyllysine 1Whole Body Imaging 1Vorinostat 1Tretinoin 1Stem Cell Transplantation 1Potassium Iodide 1Nivolumab 1Leucovorin 1LY2940680 1Isotretinoin 1Furosemide 1Floxuridine 1Erlotinib Hydrochloride 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × Granulocyte Colony-Stimulating Factor × Endocrine × Clear all
NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Masonic Cancer Center, University of Minnesota

Phase NA Completed
15 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡